Needham & Company LLC Reaffirms Buy Rating for Autolus Therapeutics (NASDAQ:AUTL)

Autolus Therapeutics (NASDAQ:AUTL)‘s stock had its “buy” rating reissued by investment analysts at Needham & Company LLC in a note issued to investors on Friday,Benzinga reports. They currently have a $10.00 price target on the stock.

A number of other research analysts also recently commented on AUTL. Truist Financial raised shares of Autolus Therapeutics to a “strong-buy” rating in a research report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Autolus Therapeutics in a research report on Wednesday, January 21st. HC Wainwright assumed coverage on shares of Autolus Therapeutics in a research note on Tuesday, February 17th. They set a “buy” rating and a $9.00 target price for the company. Finally, Zacks Research upgraded shares of Autolus Therapeutics from a “strong sell” rating to a “hold” rating in a report on Friday, March 13th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $8.50.

Autolus Therapeutics Price Performance

NASDAQ:AUTL opened at $1.21 on Friday. The stock has a market cap of $322.03 million, a PE ratio of -1.12 and a beta of 1.95. Autolus Therapeutics has a fifty-two week low of $1.11 and a fifty-two week high of $2.70. The stock’s 50-day moving average is $1.49 and its two-hundred day moving average is $1.52.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings results on Friday, March 27th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.07). The company had revenue of $24.29 million during the quarter, compared to analysts’ expectations of $23.92 million. Autolus Therapeutics had a negative return on equity of 63.76% and a negative net margin of 439.69%. On average, equities research analysts anticipate that Autolus Therapeutics will post -0.94 earnings per share for the current year.

Hedge Funds Weigh In On Autolus Therapeutics

A number of hedge funds have recently added to or reduced their stakes in AUTL. Mak Capital One LLC raised its position in Autolus Therapeutics by 15.3% during the fourth quarter. Mak Capital One LLC now owns 30,005,343 shares of the company’s stock valued at $59,711,000 after acquiring an additional 3,987,727 shares in the last quarter. Armistice Capital LLC grew its position in Autolus Therapeutics by 12.2% in the fourth quarter. Armistice Capital LLC now owns 17,500,000 shares of the company’s stock worth $34,825,000 after acquiring an additional 1,900,000 shares in the last quarter. TFG Asset Management GP Ltd grew its position in Autolus Therapeutics by 10.5% in the second quarter. TFG Asset Management GP Ltd now owns 9,500,000 shares of the company’s stock worth $21,660,000 after acquiring an additional 900,000 shares in the last quarter. Schroder Investment Management Group increased its stake in shares of Autolus Therapeutics by 12.5% during the 4th quarter. Schroder Investment Management Group now owns 9,489,345 shares of the company’s stock worth $18,694,000 after purchasing an additional 1,056,092 shares during the last quarter. Finally, Bank of America Corp DE raised its holdings in shares of Autolus Therapeutics by 108.1% during the 3rd quarter. Bank of America Corp DE now owns 2,029,593 shares of the company’s stock valued at $3,308,000 after purchasing an additional 1,054,458 shares in the last quarter. Institutional investors and hedge funds own 72.83% of the company’s stock.

Trending Headlines about Autolus Therapeutics

Here are the key news stories impacting Autolus Therapeutics this week:

• Positive Sentiment: Company reiterated 2026 guidance: management expects AUCATZYL® net product revenue of $120–$135M and a shift to positive gross margin in 2026 — a clear path to improving unit economics and cash-generation visibility. Autolus Therapeutics: Q4 Earnings Highlight Importance Of Autoimmune Data Catalysts
• Positive Sentiment: Commercial traction: AUCATZYL reported ~$23.3M net product revenue in Q4 and $74.3M for FY2025; UK launch underway after positive NICE evaluation and real‑world data show favorable activity/safety — supports revenue ramp thesis. Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
• Positive Sentiment: Analyst upgrades/price target upside: Needham reaffirmed a Buy with a $10 PT (large theoretical upside from current levels) and Truist upgraded to Strong-Buy — these notes can attract speculative buying ahead of clinical readouts. Benzinga
• Neutral Sentiment: Pipeline catalyst timeline: pivotal Phase 2 trials enrolling in lupus nephritis and pediatric ALL; initial BOBCAT Phase 1 data in progressive MS expected late 2026 — potential upside but not immediate. Press Release
• Neutral Sentiment: Company hosted an earnings call and published the transcript/slides — useful for detail on margin assumptions and cash runway into Q4 2027. Q4 2025 Earnings Call Transcript
• Negative Sentiment: Earnings miss and weak profitability metrics: Q4 EPS of ($0.34) missed consensus ($0.27); company still deeply unprofitable with a large negative net margin and negative ROE — these metrics pressure sentiment in the near term. Press Release / Slide Deck
• Negative Sentiment: Analyst caution: Some outlets (and at least one analyst note) highlight a challenging risk/reward despite strong B-ALL data, citing reliance on upcoming autoimmune and pediatric data to re‑rate the stock. Seeking Alpha Hold-perspective

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.